SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

SCHEDULE OF UNREALIZED GAINS AND LOSSES

	Initial Book Value		Cumulative Gross Unrealized Gains		Cumulative Gross Unrealized Losses		Fair Value
December 31, 2023
Investment in GMP Bio (equity securities)	$	22,640,519	$	12,706	$	-	$	22,653,225
Total	$	22,640,519	$	12,706	$	-	$	22,653,225

	Initial Book Value		Cumulative Gross Unrealized Gains		Cumulative Gross Unrealized Losses		Fair Value
December 31, 2022
Investment in GMP Bio (equity securities)	$	22,640,519	$	-	$	-	$	22,640,519
Total	$	22,640,519	$	-	$	-	$	22,640,519

SUMMARY OF CHANGES IN FAIR VALUE OF LONG-TERM INVESTMENT IN EQUITY SECURITIES

	December 31, 2023		December 31, 2022
Balance at January 1, 2023 and 2022	$	22,640,519	$	-
Contribution at cost basis		-		5,689,042
Gain on derecognition of non-financial asset		-		16,951,477
Change in fair value		12,706		-
Balance at December 31, 2023 and 2022	$	22,653,225	$	22,640,519

SUMMARY OF CHANGES IN FAIR VALUE OF DERIVATIVE LIABILITIES

The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities classified as Level 3 as of December 31, 2023 and 2022:

	December 31, 2023 Conversion Feature		December 31, 2022 Conversion Feature
Balance at January 1, 2023 and 2022	$	198,140	$	340,290
New derivative liability		-		-
Reclassification to additional paid in capital from conversion of debt to common stock		-		-
Change in fair value		225,074		(142,150	)
Balance at December 31, 2023 and 2022	$	423,214	$	198,140

SUMMARY OF ESTIMATE FAIR VALUE OF DERIVATIVE LIABILITIES

	December 31, 2023			December 31, 2022
Risk free interest		4.64% - 5.40%			0.17% - 4.0%
Market price of share		$ 0.03 - 0.05			$ 0.05 - 0.23
Life of instrument in years		0.01			0.01 - 0.33
Volatility		142.45%-236.86	%		99.80%-116.51	%
Dividend yield		0	%		0	%

SCHEDULE OF BASIC AND DILUTED WEIGHTED AVERAGE COMMON STOCK OUTSTANDING

The table below sets forth a reconciliation of the basic weighted average common stock outstanding to the diluted weighted average common stock outstanding of the Company as of December 31, 2022:

	December 31, 2022
Basic weighted average common stock outstanding		384,075,369
Add: Dilutive common stock equivalents
Stock options outstanding		2,606,054
Warrants outstanding		68,681
Convertible debt, convertible into common stock		70,549,786
Diluted weighted average common stock outstanding		457,299,890